Connection
Martin Cannon to Antigen Presentation
This is a "connection" page, showing publications Martin Cannon has written about Antigen Presentation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.122 |
|
|
|
-
Cannon MJ, O'Brien TJ, Underwood LJ, Crew MD, Bondurant KL, Santin AD. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. Expert Rev Anticancer Ther. 2002 Feb; 2(1):97-105.
Score: 0.051
-
Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Cancer. 2009 Feb 15; 115(4):800-11.
Score: 0.021
-
Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther. 2007 Oct; 7(10):1473-86.
Score: 0.019
-
Crew MD, Cannon MJ, Phanavanh B, Garcia-Borges CN. An HLA-E single chain trimer inhibits human NK cell reactivity towards porcine cells. Mol Immunol. 2005 Jun; 42(10):1205-14.
Score: 0.016
-
Wahid R, Cannon MJ, Chow M. Dendritic cells and macrophages are productively infected by poliovirus. J Virol. 2005 Jan; 79(1):401-9.
Score: 0.016